CYPH
Cypherpunk Technologies Inc. NASDAQ Listed Jan 25, 2017$0.65
After hrs
$0.65
+0.00%
Mkt Cap $37.0M
52w Low $0.23
12.1% of range
52w High $3.70
50d MA $0.96
200d MA $0.88
P/E (TTM)
—
EV/EBITDA
—
P/B
0.3x
Debt/Equity
0.0x
ROE
3.1%
P/FCF
-1.2x
RSI (14)
38.30
ATR (14)
$0.12
Beta
-0.22
50d MA
$0.96
200d MA
$0.88
Avg Volume
6.7M
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
47 Thorndike Street · Cambridge, MA 02141 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | AMC | -0.04 | -0.46 | -1033.0% | 1.20 | -2.5% | -9.2% | -4.6% | +4.8% | +16.5% | +3.1% | — |
| Mar 16, 2026 | AMC | -0.07 | -0.23 | -246.4% | 0.70 | +0.7% | +12.6% | -9.7% | -1.3% | -0.4% | +1.2% | — |
| Nov 12, 2025 | AMC | -0.24 | -0.08 | +66.7% | 2.05 | -30.2% | -14.1% | +56.2% | -11.6% | +22.2% | -1.0% | — |
| Aug 14, 2025 | AMC | -0.29 | -0.40 | -37.9% | 0.24 | +4.3% | +10.1% | +7.6% | -0.7% | -6.3% | +2.5% | — |
| May 13, 2025 | AMC | -0.38 | -0.37 | +2.6% | 0.40 | -0.5% | +2.2% | +0.7% | -2.7% | +3.4% | -8.3% | — |
| Mar 26, 2025 | AMC | -0.39 | -0.37 | +5.1% | 0.45 | -9.6% | -19.6% | -13.2% | -3.6% | -4.5% | +16.7% | — |
| Nov 13, 2024 | AMC | -0.46 | -0.44 | +4.3% | 3.00 | +0.0% | -3.7% | -5.2% | +1.5% | -2.9% | -4.1% | — |
| Aug 12, 2024 | AMC | -0.42 | -0.52 | -23.8% | 2.38 | +2.5% | +8.4% | -4.7% | +0.0% | +1.2% | +2.4% | — |
| May 13, 2024 | AMC | -0.57 | -0.51 | +10.5% | 2.83 | +1.1% | -2.8% | +1.8% | -2.1% | -4.0% | -2.3% | — |
| Mar 18, 2024 | AMC | -0.56 | -0.46 | +17.9% | 2.14 | +1.4% | +2.8% | +15.9% | +0.0% | -1.2% | -4.8% | — |
| Nov 13, 2023 | AMC | -0.48 | -0.51 | -6.2% | 1.43 | +0.0% | +9.1% | +2.6% | -0.6% | +15.1% | +13.1% | — |
| Aug 14, 2023 | AMC | -0.98 | -0.91 | +7.1% | 2.40 | +1.7% | +5.8% | -8.3% | -5.2% | -2.7% | +2.3% | — |
| May 15, 2023 | AMC | -0.90 | -3.20 | -255.6% | 4.50 | +2.2% | +17.1% | +15.7% | +4.9% | +1.6% | +1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14 | Baird | Maintains | Outperform → Outperform | — | $2.36 | $2.36 | +0.0% | +1.7% | +5.8% | -8.3% | -5.2% | -2.7% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.36 | $2.36 | +0.0% | +1.7% | +5.8% | -8.3% | -5.2% | -2.7% |
| Jul 12 | Raymond James | Maintains | Outperform → Outperform | — | $3.07 | $3.10 | +1.0% | +6.2% | +3.7% | -6.8% | -2.9% | -1.0% |
| Jun 22 | Raymond James | Maintains | Outperform → Outperform | — | $4.46 | $4.42 | -0.9% | -5.8% | -9.8% | -16.4% | -3.8% | +10.5% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $4.60 | +2.2% | +17.1% | +15.7% | +4.9% | +1.6% | +1.5% |
| Apr 13 | Mizuho | Maintains | Buy → Buy | — | $3.53 | $3.60 | +2.0% | +19.0% | -6.4% | -5.9% | +4.1% | -2.1% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.18 | $3.12 | -1.9% | -8.8% | +6.9% | +5.5% | +0.3% | +3.7% |
| Mar 27 | Raymond James | Maintains | Outperform → Outperform | — | $3.18 | $3.12 | -1.9% | -8.8% | +6.9% | +5.5% | +0.3% | +3.7% |
| Mar 17 | Mizuho | Maintains | Buy → Buy | — | $4.38 | $3.70 | -15.5% | -16.9% | -3.8% | -3.7% | -0.6% | -1.5% |
| Jan 27 | Mizuho | Maintains | Buy → Buy | — | $6.70 | $7.00 | +4.5% | -4.3% | -1.7% | +5.6% | -2.3% | -1.2% |
| Jan 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.97 | $5.19 | +4.4% | -2.2% | +10.9% | +33.4% | -9.2% | +1.1% |
| Nov 11 | Raymond James | Maintains | Outperform → Outperform | — | $6.20 | $6.35 | +2.4% | +1.0% | +12.6% | -0.6% | -5.1% | -9.6% |
| Aug 15 | Raymond James | Maintains | Outperform → Outperform | — | $12.90 | $13.40 | +3.9% | +10.9% | -2.8% | -7.2% | +2.3% | -4.5% |
| Jul 13 | Raymond James | Maintains | Outperform → Outperform | — | $11.40 | $11.60 | +1.8% | -0.9% | -2.7% | -0.9% | -0.9% | +4.6% |
| Oct 4 | Mizuho | Maintains | Buy → Buy | — | $36.50 | $37.48 | +2.7% | -1.9% | -2.0% | -7.4% | +3.4% | +0.3% |
| Sep 14 | Raymond James | Maintains | Outperform → Outperform | — | $17.70 | $17.50 | -1.1% | +1.1% | +7.8% | +31.1% | +4.7% | +4.5% |
| Mar 2 | Raymond James | Maintains | Outperform → Outperform | — | $24.30 | $25.00 | +2.9% | -3.7% | -1.3% | -11.7% | +5.4% | -6.0% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.00 | $19.00 | +0.0% | +5.3% | -1.8% | -1.8% | -3.1% | -3.7% |
| Jun 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.90 | $22.50 | +2.7% | -0.5% | -4.1% | -3.3% | +2.5% | -3.9% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.40 | $23.10 | +3.1% | +2.7% | -2.2% | -4.4% | -0.9% | -6.6% |
| Mar 17 | H.C. Wainwright | Maintains | Buy → Buy | — | $13.00 | $13.80 | +6.2% | +9.2% | -17.6% | +12.8% | -3.8% | +3.1% |
| Feb 11 | Baird | Maintains | Outperform → Outperform | — | $18.60 | $20.40 | +9.7% | +14.5% | -4.2% | -1.5% | +7.0% | +7.0% |
| Jan 8 | Raymond James | Upgrade | Market Perform → Outperform | — | $16.80 | $16.00 | -4.8% | +4.8% | +10.8% | -5.6% | -7.6% | -1.8% |
| Nov 15 | Raymond James | Downgrade | Outperform → Market Perform | — | $6.27 | $6.10 | -2.7% | +2.7% | +13.0% | +4.7% | -5.0% | -4.7% |
| Dec 19 | Raymond James | Maintains | Outperform → Outperform | — | $27.10 | $26.40 | -2.6% | -0.7% | -6.7% | -6.0% | -3.4% | +1.3% |
| Apr 12 | H.C. Wainwright | Maintains | Buy → Buy | — | $97.10 | $98.10 | +1.0% | +3.1% | -2.7% | -23.1% | +1.1% | +1.2% |
| Mar 7 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $78.50 | $78.00 | -0.6% | +11.7% | +6.0% | -0.1% | -4.2% | -2.7% |
| Mar 1 | Raymond James | Maintains | Outperform → Outperform | — | $71.40 | $76.40 | +7.0% | +14.0% | -3.4% | -0.9% | +0.8% | +11.7% |
No insider trades available.
8-K
Cypherpunk Technologies Inc. -- 8-K Filing
May 26
8-K · 2.02
!! High
Cypherpunk Technologies Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Cypher Intelligence's executive change could signal leadership transition risks or strategic repositioning, potentially affecting investor confidence and operational continuity until replacement qualifications are disclosed.
Apr 10
8-K
Unknown — 8-K Filing
Cypherpunk Technologies released its 2025 full-year earnings results, providing investors with critical insight into revenue growth, profitability, and operational performance that will determine the stock's near-term valuation trajectory.
Mar 16
8-K
Cypherpunk Technologies Inc. -- 8-K Filing
Cypherpunk Technologies (CYPH) has 180 days to restore its stock price above Nasdaq's minimum bid requirement or face delisting, with a reverse stock split being a potential remedy.
Mar 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,818,414 | $1M | New | Mar 2026 |
| 2 | Renaissance Technologies Llc | 725,120 | $576K | New | Mar 2026 |
| 3 | Arete Wealth Advisors, Llc | 12,488 | $295K | New | Mar 2026 |
| 4 | Susquehanna International Group, Llp | 262,953 | $209K | Reduced | Mar 2026 |
| 5 | Ubs Group Ag | 171,068 | $136K | Added | Mar 2026 |
| 6 | Cygnus Capital Advisors, Llc | 11,492 | $135K | New | Mar 2026 |
| 7 | Citigroup Inc | 73,022 | $85K | New | Dec 2025 |
| 8 | Northern Trust Corp | 87,562 | $70K | — | Mar 2026 |
| 9 | Key Client Fiduciary Advisors, Llc | 80,424 | $64K | Reduced | Mar 2026 |
| 10 | Hightower Advisors, Llc | 50,500 | $59K | Reduced | Dec 2025 |
| 11 | Two Sigma Investments, Lp | 66,572 | $53K | Reduced | Mar 2026 |
| 12 | Sequoia Financial Advisors, Llc | 48,000 | $38K | — | Mar 2026 |
| 13 | Simplex Trading, Llc | 39,196 | $31K | Reduced | Mar 2026 |
| 14 | Hrt Financial Lp | 37,722 | $29K | New | Mar 2026 |
| 15 | Keystone Financial Group | 11,712 | $9K | — | Mar 2026 |
| 16 | Quadrant Private Wealth Management, Llc | 11,200 | $9K | New | Mar 2026 |
| 17 | Blair William & Co/il | 10,000 | $8K | — | Mar 2026 |
| 18 | Farther Finance Advisors, Llc | 2,058 | $2K | — | Mar 2026 |
| 19 | Morgan Stanley | 972 | $1K | Reduced | Dec 2025 |
| 20 | Western Wealth Management, Llc | 800 | $636 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 262,968 | $164K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 89,230 | $56K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 71,448 | $45K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 16,182 | $10K | Feb 2026 |
Valuation
Market Cap
$37.0M
Enterprise Value
$38.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.15x
P/B
0.28x
P/S
—
P/FCF
-1.19x
EV/EBITDA
—
Shares Out
70.7M
Financials (TTM)
Revenue
$0
Net Income
-$56.9M
EBITDA
-$29.6M
Free Cash Flow
-$43.9M
Op Cash Flow
-$43.9M
EPS Basic
$0.07
EPS Diluted
$-0.02
EPS Forward
$-0.15
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$163.2M
Total Liab.
$9.7M
Total Equity
$153.5M
Cash
$14.0M
LT Debt
$0
Book Value/Sh
$2.32
Debt/Equity
0.00x
Current Ratio
35.56
Quick Ratio
35.56
Returns & Growth
ROE
3.1%
ROA
2.9%
ROIC
-11.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+104.0%
Price Returns
2W
-5.8%
1M
+27.1%
3M
+81.1%
6M
-26.1%
12M
+198.9%
Technicals
52W High
$3.70
52W Low
$0.23
50d MA
$0.96
200d MA
$0.88
RSI (14)
38.30
ATR (14)
$0.12
Beta
-0.22
Avg Volume
6.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.50
High
$5.50
Low
$5.50
Median
$5.50
Data updated apr 25, 2026 4:27am
· Source: financialmodelingprep.com